Forte Biosciences, INC 10-Q quarterly reports

Forte Biosciences announced positive topline data for its FB102 drug in a vitiligo Phase 1b trial, while also detailing its ongoing clinical development and significant cash burn.

Forte Biosciences reported a net loss of $22.1 million for Q1 2026, with research and development expenses significantly increasing, while cash reserves remain substantial following a recent public offering.

Forte Biosciences reports significant progress in its FB102 clinical programs for autoimmune diseases, backed by a strengthened cash position following recent capital raises, despite continued operating losses.

Forte Biosciences announced positive Phase 1b celiac disease trial results for FB102 and significantly strengthened its cash position through recent public offerings.

Forte Biosciences reports a net loss for Q1 2025, while progressing clinical trials for FB102 in celiac disease and non-segmental vitiligo.

Forte Biosciences reports a net loss of $28.3 million for the first nine months of 2024 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Forte Biosciences reports a net loss of $19.9 million for the first six months of 2024, while advancing its lead drug candidate, FB102, into patient studies.

Forte Biosciences reported a net loss of $7.4 million for the first quarter of 2024, while advancing its FB102 clinical trial.